Shih-Hsien Chuang

This inventor holds 18 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Antibody-Drug Conjugates. Top assignees: Ye Siang Enterprise Co., Ltd., Development Center for Biotechnology, Taivex Therapeutics Corporation. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shih-Hsien Chuang. Retrieved from https://idiyas.com/inventor/shih-hsien-chuang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 44(Granted Patents)

Location History:

Xizhi, TW (2011)
Taoyuan, TW (2015 - 2021)
New Taipei, TW (2014 - 2024)
Taipei, TW (2021 - 2024)

Company Filing History:

8 out of 10

Ye Siang Enterprise Co., Ltd.

patents

7 out of 97

Development Center for Biotechnology

patents

3 out of 8

Taivex Therapeutics Corporation

patents

4. 2 out of 3

Development Center of Biotechnology

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

Areas of Expertise:

Antibody-Drug Conjugates

Glycoprotein-Drug Conjugates

Gas Phase Filter

Fluid Filter

HEC1 Modulators

High-Throughput Screening

Tubulin Inhibitors

Indolinone Compounds

Kinase Inhibitors

Immunoconjugates

Adaptor-Drug Conjugates

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. D1034897 - Gas phase filter (2024-07-09),

2. 11998613 - Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof (2024-06-04),

3. D1023230 - Cover for a fluid filter (2024-04-16),

4. 11890562 - Filtering module (2024-02-06),

5. D968561 - Gas phase filter (2022-11-01),

6. D963792 - Cover for a fluid filter (2022-09-13),

7. D959602 - Cover for a fluid filter (2022-08-02),

8. D958935 - Cover for a fluid filter (2022-07-26),

9. D958934 - Cover for a fluid filter (2022-07-26),

10. 11384150 - Antibody-drug conjugates and uses thereof (2022-07-12),

11. 11085062 - Processes for preparing glycoprotein-drug conjugates (2021-08-10),

12. 11071736 - Modulators of HEC1 activity and methods therefor (2021-07-27),

13. 10947316 - Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof (2021-03-16),

14. 10752673 - High-throughput screening of functional antibody fragments, immunoconjugate comprising the same, and adaptor-drug conjugate for screening (2020-08-25),

15. 10588909 - Modulators of HEC1 activity and methods therefor (2020-03-17),

Title: Contributions of Shih-Hsien Chuang to Biotechnology and Patent Innovations

Introduction: Shih-Hsien Chuang is an accomplished inventor based in New Taipei, Taiwan, known for his significant contributions to the field of biotechnology. With a robust portfolio of 18 patents, he has played a pivotal role in the development of innovative solutions, particularly in the realm of therapeutic applications.

Latest Patents: Among his notable patents, one stands out: a gas phase filter related to antibody-drug conjugates that contain an anti-mesothelin antibody. This invention provides an immunoconjugate comprising an antibody with an antigen-binding fragment that specifically targets an epitope in mesothelin. The design integrates an N-glycan binding domain and an N-glycan linked to a payload A and a payload B, which may be identical or distinct. Furthermore, the disclosure encompasses a pharmaceutical composition that utilizes the immunoconjugate along with methods for treating cancer, underscoring its potential impact in oncology.

Career Highlights: Shih-Hsien Chuang has significantly contributed to various organizations, primarily Ye Siang Enterprise Co., Ltd. and the Development Center for Biotechnology. His work in these industries highlights his dedication to advancing biotechnological research and applications.

Collaborations: Throughout his career, Chuang has collaborated with esteemed colleagues such as Shih-Chieh Chuang and Wei-Kuo Kong. These partnerships have likely enhanced the breadth and depth of his research and innovations, fostering a collaborative environment conducive to groundbreaking discoveries.

Conclusion: Shih-Hsien Chuang's dedication to innovation is evidenced by his extensive patent portfolio and collaborative efforts in biotechnology. His latest advancements, particularly in therapeutic applications, hold promise for significant contributions to cancer treatment and broader medical applications. As the field continues to evolve, Chuang’s work remains influential in paving the way for future innovations.

Profile summary based on public USPTO records.